Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients

Journal of Pathology

Volumn 229, Issue 1, 2013, Pages 87-98

  Basile, Antonio ^a   Moschetta, Michele ^a   Ditonno, Paolo ^b   Ria, Roberto ^a   Marech, Ilaria ^a   De Luisi, Annunziata ^a   Berardi, Simona ^a   Frassanito, Maria Antonia ^a   Angelucci, Emanuele ^c   Derudas, Daniele ^c   Specchia, Giorgina ^a   Curci, Paola ^a   Pavone, Vincenzo ^d   Rossini, Bernardo ^d   Ribatti, Domenico ^a   Bottazzi, Barbara ^e   Mantovani, Alberto ^e   Presta, Marco ^f   Dammacco, Franco ^a   Vacca, Angelo ^a,g  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b DI VENERE HOSPITAL   (Italy)

^c Ospedale Oncologico A Businco   (Italy)

^d Haematology Unit   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF BRESCIA   (Italy)

^g POLICLINICO   (Italy)

Author keywords

angiogenesis; bone marrow microenvironment; FGF2; MGUS; multiple myeloma; pentraxin 3

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 6; INTERLEUKIN 8; MATRIGEL; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; STROMAL CELL DERIVED FACTOR 1ALPHA;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW; CELL INTERACTION; CELL VIABILITY; CHEMOTAXIS; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; WESTERN BLOTTING; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE MARROW CELLS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL ADHESION; CELL ADHESION MOLECULES; CELL COMMUNICATION; CELL LINE; CELLULAR MICROENVIRONMENT; CHEMOTAXIS; CHICK EMBRYO; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; CYTOKINES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 84872873607     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4081     Document Type: Article

References (35)

1. Raab MS, Podar K, Breitkreutz I, et al., Multiple myeloma. Lancet 2009; 374: 324-339.
2. Podar K, Tai YT, Hideshima T, et al., Emerging therapies for multiple myeloma. Expert Opin Emerging Drugs 2009; 14: 99-127.
3. Vacca A, Ribatti D,. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199.
4. Vacca A, Ria R, Semeraro F, et al., Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003; 102: 3340-3348.
5. Italiano Jr JE, Richardson JL,. Angiogenesis is regulated by novel mechanism: pro- and anti-angiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: 1227-1233.
6. Seghezzi G, Patel S, Ren CJ, et al., Fibroblast growth factor-2 (FGF2) induces vascular endothelial factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659-1673.
7. Jakob C, Sterz J, Zavrski I, et al., Angiogenesis in multiple myeloma. Eur J Cancer 2006; 42: 1581-1590.
8. Alessi P, Leali D, Camozzi M, et al., Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw 2009; 20: 225-234.
9. Kanazawa S, Fujiwara T, Matsuzaki S, et al., bFGF regulates PI3-kinase-Rac1-JNK pathway and promotes fibroblast migration in wound healing. PLoS One 2010; 5: e12228.
10. Bottazzi B, Vouret-Cravari V, Bastone A, et al., Multimer formation and ligand recognition by long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817-32823.
11. Lee GW, Lee TH, Vilcek J,. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentraxin family of acute phase proteins. J Immunol 1993; 150: 1804-1812.
12. Mantovani A, Garlanda C, Bottazzi B,. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21: 43-47.
13. Presta M, Camozzi M, Salvatori G, et al., Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11: 723-738.
14. Camozzi M, Rusnati M, Bugatti A, et al., Identification of an antiangiogenic FGF2-binding site in N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006; 281: 22605-22613.
15. Rusnati M, Camozzi M, Moroni E, et al., Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92-99.
16. Leali D, Bianchi R, Bugatti A, et al., Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived antiangiogenic pentapeptide. J Cell Mol Med 2010; 14: 2109-2121.
17. Introna M, Alles VV, Castellano M, et al., Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87: 1862-1872.
18. Alles VV, Bottazzi B, Peri G, et al., Inducible expression of PTX3, a new member of the pentraxin gene family, in human mononuclear phagocytes. Blood 1994; 84: 3483-3493.
19. Berardi S, Caivano A, Ria R, et al., Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene 2012; 31: 2258-2269.
20. Vacca A, Scavelli C, Montefusco V, et al., Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005; 23: 5334-5346.
21. De Luisi A, Ferrucci A, Coluccia AML, et al., Lenalidomide restrains mobility and overangiogenic potential of bone marrow endothelial cells in patients with acute multiple myeloma. Clin Cancer Res 2011; 17: 1935-1946.
22. ® assay in vitro. Microvasc Res 2004; 67: 117-124.
23. Ribatti D, Nico B, Vacca A, et al., The gelatin sponge-chorioallantoic membrane assay. Nature Protoc 2006; 1: 85-91.
24. Lambert KE, Huang H, Mythreye K, et al., The type III transforming growth factor-β receptor inhibits proliferation, migration, and adhesion in human myeloma cells. Mol Biol Cell 2011; 22: 1463-1472.
25. Vacca A, Ribatti D, Presta M, et al., Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073.
26. Ribatti D, Nico B, Vacca A,. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 2006; 25: 4257-4266.
27. Beenken A, Mohammadi M,. The FGF family: biology, pathophysiology and therapy. Nature Rev Drug Discov 2009; 8: 235-253.
28. Murakami M, Nguyen LT, Zhuang ZW, et al., The FGF system has a key role in regulating vascular integrity. J Clin Invest 2008; 118: 3355-3366.
29. Murakami M, Nguyen LT, Hatanaka K, et al., FGF-dependent regulation of VEGF receptor 2 expression in mice. J Clin Invest 2011; 121: 2668-2678.
30. Mantovani A, Garlanda C, Doni A, et al., Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008; 28: 1-13.
31. Vänskä M, Koivula I, Hämäläinen S, et al., High pentraxin 3 level predicts septic shock and bacteremia at the onset of febrile neutropenia after intensive chemotherapy of hematologic patients. Haematologica 2011; 96: 1385-1389.
32. Diamandis EP, Goodglick L, Planque C, et al., Pentraxin-3 is a novel biomarker of lung carcinoma. Clin Cancer Res 2011; 17: 2395-2399.
33. Yoon KA, Chae YM, Cho JY,. FGF2 stimulates SDF-1 expression through the Erm transcription factor in Sertoli cells. J Cell Physiol 2009; 220: 245-256.
34. Wempe F, Lindner V, Augustin HG,. Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 2471-2478.
35. Kumar S, Witzig TE, Timm M, et al., Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104: 1159-1165.